A Healthcare Cost and Resource Utilization Analysis of Intravenous and Oral Agents in the Treatment of Metastatic Renal Cell Carcinoma
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 发起方
- 试验地点
- 1
- 主要终点
- Composite of Resource Utilization for patients treated with IV drugs used in the first-line treatment of mRCC
研究概览
简要总结
A retrospective study to evaluate healthcare cost and resource utilization for patients with metastatic renal cell carcinoma who have been treated with IV or oral agents
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis with metastatic renal cell carcinoma
- •Prescription/administration of one of the IV or oral agents examined in the study
排除标准
- •Patients with other primary cancer diagnosis before RCC diagnosis
- •Patients with pregnancy or HIV/AIDS
结局指标
主要结局
Composite of Resource Utilization for patients treated with IV drugs used in the first-line treatment of mRCC
时间窗: Up to 63 months
Total numbers and rates of inpatient, outpatient, and emergency room visits per patient will be calculated.
Distribution of Healthcare costs for patients treated with oral drugs used in the first-line treatment of Metastatic renal cell carcinoma (mRCC)
时间窗: Up to 63 months
All-cause healthcare costs will be calculated in the first-line oral cohort as per-patient-per-month (PPPM) costs.
Composite of Resource Utilization for patients treated with oral drugs used in the first-line treatment of mRCC
时间窗: Up to 63 months
Total numbers and rates of inpatient, outpatient, and emergency room visits per patient will be calculated.
Distribution of Healthcare costs for patients treated with IV drugs used in the first-line treatment of mRCC
时间窗: Up to 63 months
All-cause healthcare costs will be calculated in the first-line IV cohort as per-patient-per-month (PPPM) costs.
次要结局
- Medication Possession Ratio (MPR) for patients treated with IV drugs used in the first-line treatment of mRCC(Up to 63 months)
- Medication Possession Ratio (MPR) for patients treated with oral drugs used in the first-line treatment of mRCC(Up to 63 months)